Navigation Links
The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
Date:8/20/2013

result of the outcomes trial IMPROVE-IT for ezetimibe is the most highly anticipated near-term event in the dyslipidemia market. Positive data from this trial will have a significant effect on physician prescribing and provide further validation of the LDL-C hypothesis, which will impact emerging LDL-C lowering agents such as the PCSK9 inhibitors. These agents will initially target the most high-risk patients. Launching in a specific patient subpopulation with the intention of gaining a broader label is an established development strategy, and one previously employed for prescription omega-3 fatty acids, Amarin's Vascepa and AstraZeneca's Epanova.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
7. Ophthalmic Drugs: World Market Prospects 2012-2022
8. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
9. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
10. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... N.J. , March 26, 2015 IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... of ANDA submissions now pending at the FDA to ... CEO of the Company, commented, "On March 2, 2015, ...
(Date:3/26/2015)...  CNBC profiled MJ Freeway , a business software ... "How I Did It," which features companies with unique paths ... released yesterday, illustrates how two tech entrepreneurs from ... the marijuana industry. ... Poinsett and Jessica Billingsley used their experience in ...
(Date:3/26/2015)... 26, 2015 Editor Note: ... bottom . Investor-Edge has initiated coverage on ... Salix Pharmaceuticals Ltd (NASDAQ: SLXP ), Hospira Inc. ... ), and Akorn Inc. (NASDAQ: AKRX ). Free ... http://get.Investor-Edge.com/pdf/?c=Mylan&d=26-Mar-2015&s=MYL . The US markets declined on Wednesday, March ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 3Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 4Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 5
... LITTLE FALLS, N.J., Feb. 2, 2011 Projects ... provider of continuing medical education (CME/CE) activities, previously ... game-changing Living Medical eTextbook. Now the iPhone app ... recognized by iMedicalApps ( www.imedicalapps.com ) as one ...
... and PRINCETON, N.J., Feb. 2, 2011 Eli Lilly ... Squibb Company (NYSE: BMY ) announced today ... two global Phase III studies evaluating necitumumab, an investigational ... cell lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO) ...
Cached Medicine Technology:Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 3Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 4Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 5Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 6Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 7Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 8Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 9Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 10
(Date:3/27/2015)... San Diego, CA (PRWEB) March 27, 2015 ... will launch its Protect Our Children (POC) NOW! vitamin ... at the Medical University of South Carolina (MUSC), and ... POC will be available at no cost to a ... less gestation who live within these two service areas. ...
(Date:3/27/2015)... 27, 2015 When struck with the ... to know where to begin. The latest eBook ... accident attorney, offers accident victims a clear and concise ... to ensure their personal injury claim is seen through ... the first actions that should be taken immediately following ...
(Date:3/27/2015)... Trail mix is the perfect, healthy snack for families on ... the game! It’s portable, lightweight and provides a wide range ... new line of specialty trail mixes that satisfy your hunger ... with nutritious, 100% all natural ingredients. , These tasty combinations ... and fiber to your diet and boost energy. The mixes ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Approximately ... for Healthy Kids Coalition Lobby Day to lobby ... Health Improvement Program (SHIP). Everlast Climbing was ... PE Bill SF343/HF498 which would strengthen physical education ... student assessments and other measures to strengthen physical ...
(Date:3/27/2015)... Since September 2014, the country singer has been traveling ... been in retirement for a period of 13 years. Many ... to touring, and concert events have been booking quickly in ... out for the two shows recently scheduled for May 8 ... inventory of discounted Garth Brooks tickets for sale. , The ...
Breaking Medicine News(10 mins):Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2
... Weinberg is the first recipient of the science prize inaugurated ... Eva Klein. The prize is awarded in person by Crown ... 2008. The prizewinner, who is to be a leading international ... Institutet in Stockholm for two weeks to give lectures and ...
... You Be Ready with that Confident ... ... Freshening Teeth Cleaners, an effective way to,clean teeth and freshen breath on-the-go. ... of,teeth, leaving them feeling smooth and clean., A great smile is ...
... /PRNewswire/ - There is new hope for vertigo,and ... DizzyFIX,patients with vertigo can now treat themselves. Studies ... visual device helps treat the most common,type of ... DizzyFIX has received a number of medical research ...
... Sequences of DNA in the human genome that originated ... our bodies and are even essential for a healthy ... of Microbiology Today. , Retrovirus infections represent the most ... its genome into the DNA of the host cell, ...
... REDWOOD CITY, Calif., Jan. 29 Maxygen, Inc.,(Nasdaq: ... of,improved protein drugs, will host a conference call to ... results at 11:30 a.m.,ET (8:30 a.m. PT) on Tuesday, ... host the call. A press release announcing,Maxygen,s fourth quarter ...
... Gross Proceeds Expected to Be Approximately $168.6 Million, ... or the "Company") announced today that it has agreed ... Investment Bank, as sole,underwriter, in an underwritten public offering. ... option to purchase up to an additional,585,000 shares of ...
Cached Medicine News:Health News:Kimberly-Clark Launches DentaBurst(TM) Freshening Teeth Cleaners 2Health News:All Star Sales Introduces DizzyFIX a New Treatment for Vertigo and Dizziness 2Health News:Maxygen to Host Fourth Quarter and Year End 2007 Financial Results Conference Call on February 12, 2008 2Health News:Ventas Enters Agreement to Sell Common Stock 2Health News:Ventas Enters Agreement to Sell Common Stock 3Health News:Ventas Enters Agreement to Sell Common Stock 4Health News:Ventas Enters Agreement to Sell Common Stock 5
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
... Featuring new technology, such as a ... shaft and lens housings, this arthroscope has ... accomplished by EO, Steris and steam autoclaving ... diameters. Light post/adapters to fit ACMI, Wolf, ...
... The Passport II delivery device is the ... for C11UB. Its simple-to-use syringe technology allows ... a small incision. The blue colored plunger ... to protect the haptics during insertion. The ...
Medicine Products: